Tier 3 — preclinical

Preclinical evidence for quercetin against inflammatory bowel disease: a meta-analysis and systematic review

Shuangyuan Hu, Maoyaun Zhao, Wei Li, Pengfei Wei, Qingsong Liu, Shuanglan Chen, Jinhao Zeng, Xiao Ma, Jianyuan Tang
Inflammopharmacology 2022 30(6):2035-2050

Bibliography

PubMed
PMID 36227442
DOI
10.1007/s10787-022-01079-8
Funding
Indexed grant support: 82074397 — the National Natural Science Foundation of China; 21-Y17 — the "Hundred Talents Program" of the Hospital of Chengdu University of Traditional Chinese Medicine. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSystematic review and meta-analysis of animal inflammatory-bowel studies
ModelPreclinical evidence synthesis
Sample11 studies; 199 animals
InterventionQuercetin in experimental intestinal inflammation
DurationExperiment-specific schedules
EndpointsInflammatory measures; Oxidative-stress measures

What the study showed, in plain terms

Published in 2022, this source examined gut and intestinal health. Design: Systematic review and meta-analysis of animal inflammatory-bowel studies. Sample/model: 11 studies; 199 animals. The exposure or intervention was Quercetin in experimental intestinal inflammation. Follow-up or treatment period: Experiment-specific schedules.

Selected disease, histology, inflammatory, and antioxidant measures favored quercetin.

Low methodological quality and small animal studies limit validity. The review does not demonstrate treatment efficacy in people with Crohn's disease or ulcerative colitis.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Gut Health: Microbiome and Barrier Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Selected disease, histology, inflammatory, and antioxidant measures favored quercetin.
  • The recorded outcome domains were Inflammatory measures; Oxidative-stress measures.
  • The result applies to the tested exposure: Quercetin in experimental intestinal inflammation; Experiment-specific schedules.

What this study can and cannot tell us

  • Low methodological quality and small animal studies limit validity. The review does not demonstrate treatment efficacy in people with Crohn's disease or ulcerative colitis.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology